Joos B - Search Results

1

Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection.

Trkola A, Kuster H, Leemann C, Ruprecht C, Joos B, Telenti A, Hirschel B, Weber R, Bonhoeffer S, Günthard HF; Swiss HIV Cohot Study. Trkola A, et al. Among authors: joos b. J Virol. 2003 Dec;77(24):13146-55. doi: 10.1128/jvi.77.24.13146-13155.2003. J Virol. 2003. PMID: 14645571 Free PMC article. Clinical Trial.

2

Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol.

Rusert P, Fischer M, Joos B, Leemann C, Kuster H, Flepp M, Bonhoeffer S, Günthard HF, Trkola A. Rusert P, et al. Among authors: joos b. Virology. 2004 Aug 15;326(1):113-29. doi: 10.1016/j.virol.2004.05.022. Virology. 2004. PMID: 15262500 Free article.

3

Cellular viral rebound after cessation of potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 RNA encoding nef.

Fischer M, Joos B, Hirschel B, Bleiber G, Weber R, Günthard HF; Swiss HIV Cohort Study. Fischer M, et al. Among authors: joos b. J Infect Dis. 2004 Dec 1;190(11):1979-88. doi: 10.1086/425983. Epub 2004 Nov 3. J Infect Dis. 2004. PMID: 15529263 Free article.

4

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.

Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, Manrique A, Huber M, Rehr M, Oxenius A, Weber R, Stiegler G, Vcelar B, Katinger H, Aceto L, Günthard HF. Trkola A, et al. Among authors: joos b. Nat Med. 2005 Jun;11(6):615-22. doi: 10.1038/nm1244. Epub 2005 May 8. Nat Med. 2005. PMID: 15880120 Clinical Trial.

5

Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.

Rusert P, Kuster H, Joos B, Misselwitz B, Gujer C, Leemann C, Fischer M, Stiegler G, Katinger H, Olson WC, Weber R, Aceto L, Günthard HF, Trkola A. Rusert P, et al. Among authors: joos b. J Virol. 2005 Jul;79(13):8454-69. doi: 10.1128/JVI.79.13.8454-8469.2005. J Virol. 2005. PMID: 15956589 Free PMC article.

6

Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions.

Joos B, Trkola A, Fischer M, Kuster H, Rusert P, Leemann C, Böni J, Oxenius A, Price DA, Phillips RE, Wong JK, Hirschel B, Weber R, Günthard HF; Swiss HIV Cohort Study. Joos B, et al. J Virol. 2005 Jul;79(14):9026-37. doi: 10.1128/JVI.79.14.9026-9037.2005. J Virol. 2005. PMID: 15994796 Free PMC article.

7

HIV replication elicits little cytopathic effects in vivo: analysis of surrogate markers for virus production, cytotoxic T cell response and infected cell death.

Funk GA, Oxenius A, Fischer M, Opravil M, Joos B, Flepp M, Weber R, Günthard HF, Bonhoeffer S. Funk GA, et al. Among authors: joos b. J Med Virol. 2006 Sep;78(9):1141-6. doi: 10.1002/jmv.20674. J Med Virol. 2006. PMID: 16847964

8

In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.

Manrique A, Rusert P, Joos B, Fischer M, Kuster H, Leemann C, Niederöst B, Weber R, Stiegler G, Katinger H, Günthard HF, Trkola A. Manrique A, et al. Among authors: joos b. J Virol. 2007 Aug;81(16):8793-808. doi: 10.1128/JVI.00598-07. Epub 2007 Jun 13. J Virol. 2007. PMID: 17567707 Free PMC article.

Recently, passive immunization of human immunodeficiency virus (HIV)-infected individuals with monoclonal antibodies (MAbs) 2G12, 2F5, and 4E10 provided evidence of the in vivo activity of 2G12 but raised concerns about the function of the two membrane-proximal external region (M …

Recently, passive immunization of human immunodeficiency virus (HIV)-infected individuals with monoclonal antibodies (MAbs) 2G12, 2F5, and 4 …

9

Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes.

Kaiser P, Joos B, Niederöst B, Weber R, Günthard HF, Fischer M. Kaiser P, et al. Among authors: joos b. J Virol. 2007 Sep;81(18):9693-706. doi: 10.1128/JVI.00492-07. Epub 2007 Jul 3. J Virol. 2007. PMID: 17609262 Free PMC article. Clinical Trial.

10

In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers.

Trkola A, Kuster H, Rusert P, von Wyl V, Leemann C, Weber R, Stiegler G, Katinger H, Joos B, Günthard HF. Trkola A, et al. Among authors: joos b. J Virol. 2008 Feb;82(3):1591-9. doi: 10.1128/JVI.01792-07. Epub 2007 Nov 21. J Virol. 2008. PMID: 18032508 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

138 results

Search Page

Filters